Attana delivers instrument to The Centre for BioNano Interactions at University College Dublin
Stockholm, November 16 th, 2015. The Centre for BioNano Interactions, School of Chemistry and Chemical Biology at University College Dublin, has purchased an Attana Cell™ 200 instrument. The group will use the Attana instruments to understand, classify and predict nanoparticle coronas physicochemical properties.
Under the supervision of Professor Kenneth A Dawson, the group at CBNI work with Nanomedicine and Nanosafety applications. The aim is to fundamentally understand the interactions between the nanoparticle interface and the biological milieu surrounding it. The milieu is set up by proteins and other biomolecules that forms the nanoparticle interface, the so-called “corona”. The corona forms the bionanointerface that determines the fate and behaviour of nanomaterials.
The group will use the Attana instruments to understand, classify and predict nanoparticle coronas physicochemical properties. This offers a novel approach to screen for toxicity at early stages of product development and for regulatory purposes.
“The Attana Cell 200 will be an important tool complementing our other techniques. We have a tradition of successfully implementing novel technologies into efficient research tools. The ability to perform kinetic interaction analysis between nanoparticles and cells add a crucial aspect in our research” comments Prof. Dawson.
Attana CEO, Teodor Aastrup adds, “We are delighted that CBNI and Prof. Dawson has put their trust in the system and services Attana provides. This is an important development of our joint collaboration, and we anticipate significant scientific results in the near future.”
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 70 15676765
Our team provide customers with biologically relevant information to enhance their success rate and efficiency of research and development process. Our world leading cell interaction technology have been validated by academic institutions, biotech companies and big-pharma across the world. With a strong focus on characterizing molecular interactions exactly as they occur in the human body, Attana is committed to offer tools and services with the goal of enhancing success rates and efficiencies in the complex process of developing pharmaceuticals. Attana’s 3 rd generations biosensors are today used to determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
We are located in Stockholm and have a strong footprint in Europe and Asia. www.attana.com